REtinal Detachment Outcomes Study
Launched by CHU DE QUEBEC-UNIVERSITE LAVAL · May 16, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The REtinal Detachment Outcomes Study is a clinical trial designed to find the best surgical methods for treating a specific type of eye condition called rhegmatogenous retinal detachment (RRD). This study will compare two surgical techniques: one that uses a method called pars plana vitrectomy (PPV) alone and another that combines PPV with a scleral buckle (PPV-SB). Additionally, the study will look at two types of gas used during the surgery: sulfur hexafluoride (SF6) and perfluoropropane (C3F8). Researchers want to learn which combination of these techniques and gases leads to the best results in terms of the eye healing properly, improving vision, and minimizing complications over a year after surgery.
To participate, individuals must be at least 18 years old and diagnosed with RRD. However, some conditions, like certain types of severe retinal issues or previous eye surgeries, may prevent someone from joining. Participants will undergo surgery and be monitored for a year using various imaging techniques and questionnaires to assess their recovery and quality of life. This trial is significant because it aims to provide new insights that can help doctors make better treatment decisions for patients with RRD, based on strong evidence rather than past experiences or smaller studies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • Diagnosis of rhegmatogenous retinal detachment
- Exclusion Criteria, retinal detachment with:
- • Proliferative vitreoretinopathy (PVR) grade ≥C2
- • Chronic RRD with duration \>3 months
- • Proliferative diabetic retinopathy with tractional retinal detachment (RD)
- • Macular holes
- • Epiretinal membrane grade 3 or 4
- • Traumatic RD
- • Giant retinal tears
- • Retinal dialysis
- • Foveoschisis
- • Wet age-related macular degeneration
- • Endophthalmitis
- • Acute retinal necrosis
- • Coats disease
- • Retinopathy of prematurity
- • Retinoschisis
- • Retinal colobomas
- • Prior glaucoma surgery or strabismus surgery (favoring PPV only)
- • Superior RD extent less than 3 clock hours (favoring PPV only)
About Chu De Quebec Universite Laval
CHU de Québec-Université Laval is a leading academic health center in Canada, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, it leverages its extensive network of healthcare professionals, researchers, and state-of-the-art facilities to conduct innovative clinical studies across various therapeutic areas. With a strong emphasis on collaboration and ethical standards, CHU de Québec-Université Laval aims to translate scientific discoveries into effective treatments, enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Québec, Quebec, Canada
Patients applied
Trial Officials
Ali Dirani, MD MSc MPH
Principal Investigator
CHU de Québec - Université Laval
Mélanie Hébert, MD MSc
Principal Investigator
CHU de Québec - Université Laval
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported